RxDoctor Payments Data

Manuel Diaz, MD

Internal Medicine · Gainesville, FLNPI 1568665859

Payments from drug & device makers

$12,766in general payments, 2019–2025

Across 517 payments — averaging $24.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • Amgen$1K
  • Lilly USA, LLC$1K
  • AstraZeneca$1K
  • Boehringer Ingelheim$890
  • AbbVie$765
  • plus $5K from 35 others

What the payments were for

  • Food & beverage$12,64799%
  • Education$1191%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,766 in reported general payments places this provider in the 90th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$242,866
Medicare patients
385
Services billed
7,880

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin113$128,975
TrulicityDulaglutide65$109,284
OzempicSemaglutide50$84,448
EliquisApixaban61$62,543
RybelsusSemaglutide34$43,253
MounjaroTirzepatide23$37,878
JanuviaSitagliptin Phosphate15$22,086
Tresiba Flextouch U-200Insulin Degludec21$13,807
EntrestoSacubitril/Valsartan24$13,612
Trelegy ElliptaFluticasone/Umeclidin/Vilanter16$13,141
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog13$9,854
Atorvastatin Calcium614$6,766
Ezetimibe160$4,227
Levemir FlexpenInsulin Detemir12$3,718
Rosuvastatin Calcium264$3,542

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$1,252$147,16288 claims
Boehringer IngelheimJardiance$890$128,975113 claims
Novo NordiskOzempic, Rybelsus$2,223$127,70184 claims
PfizerEliquis$673$62,54361 claims
MerckJanuvia$97$22,08615 claims
NovartisEntresto$183$13,61224 claims
GSKTrelegy Ellipta$197$13,14116 claims
AbbVieSynthroid$765$1,01918 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Gainesville

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →